L19IL2/L19TNF

Phase 2Small molecule

L19IL2/L19TNF is one of 10 small molecule programs targeting Locally Advanced Basal Cell Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Locally Advanced Basal Cell CarcinomaRecruiting

Locally Advanced Cutaneous Squamous Cell CarcinomaRecruiting

Melanoma Stage IIIRecruiting

Locally Advanced Basal Cell CarcinomaPhase 2

Recruiting

Locally Advanced Cutaneous Squamous Cell CarcinomaPhase 2

Recruiting

Melanoma Stage IIIPhase 2

Recruiting

Competition

Competitive Landscape

10 competitors in Melanoma Stage III

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Phase 2

3 2

Keytruda

Merck & Co.

Phase 2

2 3

Mektovi

Pfizer

Phase 2

2 4

Yervoy

Bristol-Myers Squibb

Phase 2

2 5

Gleevec

Novartis

Phase 2

1 6

Braftovi

Pfizer

Phase 1

1 7

L19TNF

PPhilogen S.p.A.

Phase 2

1 8

Interleukin 2

EEssen Biotech

Phase 2

1 9

L19IL2

PPhilogen S.p.A.

Phase 2

1 10

L19IL2/L19TNF

PPhilogen S.p.A.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Recruiting

Melanoma Stage III

NCT06284590

Q1 2031

Phase 2Recruiting

Locally Advanced Basal Cell Carcinoma

NCT07227350

Phase 2Recruiting

Locally Advanced Cutaneous Squamous Cell Carcinoma

NCT07228442

Phase 2Recruiting

Locally Advanced Basal Cell Carcinoma

NCT07227870

Clinical

Trials by Indication[1]

Locally Advanced Basal Cell Carcinoma2 trials

A Phase 2 Controlled Randomized Study of the Efficacy of L19IL2 or L19TNF or L19IL2/L19TNF Intralesional Injections for the Treatment of Locally Advanced Basal Cell Carcinoma (LaBCC)

Recruiting·PPhilogen S.p.A.·Phase 2·NCT07227350·180 enrolled

A Phase 2 Study of Intratumoral Administration of L19IL2/L19TNF in Locally Advanced Basal Cell Carcinoma Patients Progressing or Intolerant to Systemic Treatment.

Recruiting·PPhilogen S.p.A.·Phase 2·NCT07227870·92 enrolled

Skin Cancer1 trial

L19IL2/L19TNF in Skin Cancer Patients

Unknown status·PPhilogen S.p.A.·Phase 2·NCT05329792·70 enrolled

Tumor1 trial

Intratumoral Administration of L19IL2/L19TNF

Completed·PPhilogen S.p.A.·Phase 2·NCT02076633·21 enrolled

Melanoma Stage III1 trial

A Phase 2, Three-arm, Randomized Study of the Efficacy of Intratumorally Administered L19IL2 or L19TNF or L19IL2/L19TNF, All in Combination With Systemic Anti-PD1 Pembrolizumab, in Stage III and IV Unresectable Melanoma Patients With Resistance to or Progressing Upon Anti-PD1 Checkpoint Inhibitors and With Presence of Injectable Metastases

Recruiting·PPhilogen S.p.A.·Phase 2·NCT06284590·162 enrolled

Locally Advanced Cutaneous Squamous Cell Carcinoma1 trial

A Phase 2 Study of Intratumoral Administration of L19IL2/L19TNF in Locally Advanced Cutaneous Squamous Cell Carcinoma Patients Progressing on or Intolerant to Systemic Treatment

Recruiting·PPhilogen S.p.A.·Phase 2·NCT07228442·92 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for L19IL2/L19TNF. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — L19IL2/L19TNF compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for L19IL2/L19TNF. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Philogen S.p.A. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: PPhilogen S.p.A.

L19IL2/L19TNF

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q1 2031

Trials by Indication[1]

Locally Advanced Basal Cell Carcinoma2 trials

Skin Cancer1 trial

Tumor1 trial

Melanoma Stage III1 trial

Locally Advanced Cutaneous Squamous Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News